Subscribe To

Price Alert Latest News Economic Calendar News

MSSTF / Mindset Pharma identifies additional drug candidates from 'Family 3' compounds

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug candidates, and will initiate proof of concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive take-home medication. “Our scientists designed and developed a unique class of novel and patentable compounds, our ‘Family 3,' which have shown promise as a substitute for microdosing approaches due to their low activity at the 5-HT2A receptor,” said James Lanthier, CEO of Mindset. Read More

Demo Live Account See Partner Details

Content Topics

Science

Strategic

Acquisition

Corp

Alpha

Ssaau

Mindset

Pharma

Identifies

Additional

Candidates

family

Compounds

Stock

MSSTF

Posted: Feb 3 2022, 08:49

Author Name: Proactive Investors

MSSTF News

By Proactive Investors
August 31, 2023

Mindset Pharma to be acquired by Otsuka Pharmaceutical in all-cash deal

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has agreed to be acquired by Otsuka Pharmaceutical Co, Ltd, through its wholly-owned Ots

By Proactive Investors
June 22, 2023

Mindset Pharma's Phase 2 psilocin prodrug study gets green light from UK regulators

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has received approval from the UK Medicines and Healthcare products Regulatory Authority and the Research E

By Proactive Investors
April 26, 2023

Mindset Pharma files two international patent applications under the Patent Cooperation Treaty

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has filed two international patent applications under the Patent Cooperation Treaty (PCT) to prote

By Proactive Investors
March 28, 2023

Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeutics

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF). is expanding its drug discovery efforts into novel non-hallucinogenic therapeutics in light of the success

By Proactive Investors
March 6, 2023

Mindset Pharma and PharmAla complete first sale of pharmaceutical-grade psilocybin into growing Australian market via sales partnership

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said PharmAla Biotech (CSE:MDMA) Holdings Inc has completed the first sale of a quantity of Mindset's pharm

By Proactive Investors
February 2, 2023

Mindset Pharma receives another allowance for US patent application expanding composition of matter for Family 1 psilocybin analogs

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office has granted allowance for another of its Family 1 p

By Proactive Investors
January 20, 2023

Mindset Pharma receives allowance for US patent application covering lead psychedelic therapeutic candidate

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors that the US Patent and Trademark Office (USPTO) has granted allowance for its patent applica

By GlobeNewsWire
December 6, 2022

Mindset Pharma to Participate in Upcoming Conferences in December 2022

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.